| Program | Indication | Discovery | Preclinical | PhaseⅠ | PhaseⅡ | PhaseⅢ |
| CAR-T Therapy | ||||||
| GHR106-CAR-T | Cancer |
|
||||
| RP215-CAR-T | Cancer |
|
||||
| PTG-01 | Acute Lymphoblastic Leukemia (ALL) |
|
||||
| Antibody Therapy | ||||||
| Anti-Scg3 Therapeutic Antibody | Diabetic Retinopathy (DR) |
|
||||
| hGHR106 | Cancer |
|
||||
| RP215 | Cancer |
|
||||
| CD3XCD20 bsAb | Lymphomas |
|
||||
| Cl3hmAb | Acquired Immune Deficiency Syndrome (AIDS) |
|
||||
| Protein Therapy | ||||||
| P75NEURO | Neurological Diseases |
|
||||
| P11 | Type 2 Diabetes |
|
||||
| Angiocidin | Acute Myeloid Leukemia |
|
||||
| TT-173 | Surgical Bleeding and Trauma |
|
||||
| Oncolytic Virus | ||||||
| RV-scFv-PDL1 | Cancer |
|
||||
| OV-FV-01 | Cancer |
|
||||
Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc.
2200 Smithtown Avenue, Room 1, Ronkonkoma, |
 |
Opening Hours
Monday — Sunday: 9am — 6pm |